Kevin Kozak
Gründer bei Notes Media Group LLC
Profil
Kevin Kozak is the founder of Notes Media Group LLC.
He is currently working as a Medical Director at Mercy Health System Corp.
He previously worked as the Chief Medical Officer at Novelos Therapeutics, Inc. from 2013 to 2014 and at Cellectar Biosciences, Inc. He holds a doctorate degree from Vanderbilt University School of Medicine, which he received in 2003.
Aktive Positionen von Kevin Kozak
Unternehmen | Position | Beginn |
---|---|---|
Mercy Health System Corp.
Mercy Health System Corp. Hospital/Nursing ManagementHealth Services Mercy Health System Corp. engages in the operations of regional health systems of hospitals, clinics, and specialty care centers. Its services include orthopedic surgery; pre-hospital emergency services and training; neurosurgery; heart and vascular; cancer care; and plastic and reconstructive surgery. The company was founded in 1895 and is headquartered in Janesville, WI. | Corporate Officer/Principal | - |
Notes Media Group LLC
Notes Media Group LLC Packaged SoftwareTechnology Services Notes Media Group LLC develops virtual reality games. The company was founded in 2015 and is headquartered in Chapel Hill, NC. | Gründer | - |
Ehemalige bekannte Positionen von Kevin Kozak
Unternehmen | Position | Ende |
---|---|---|
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Technik-/Wissenschafts-/F&E-Leiter | 12.02.2014 |
CELLECTAR BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Kevin Kozak
Vanderbilt University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CELLECTAR BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
Mercy Health System Corp.
Mercy Health System Corp. Hospital/Nursing ManagementHealth Services Mercy Health System Corp. engages in the operations of regional health systems of hospitals, clinics, and specialty care centers. Its services include orthopedic surgery; pre-hospital emergency services and training; neurosurgery; heart and vascular; cancer care; and plastic and reconstructive surgery. The company was founded in 1895 and is headquartered in Janesville, WI. | Health Services |
Notes Media Group LLC
Notes Media Group LLC Packaged SoftwareTechnology Services Notes Media Group LLC develops virtual reality games. The company was founded in 2015 and is headquartered in Chapel Hill, NC. | Technology Services |